Activation of the TRIO–RAC–RICTOR–mTOR signaling by the α10 subunit promotes tumor cell survival, and inhibitors of RAC and mTOR have shown anti-tumor effects in vivo, providing a potential therapeutic strategy for high-risk leiomyosarcoma patients [18]. This evidence concerns the gene AKT1 and leiomyosarcoma.